8-K: Adial Pharmaceuticals Faces Nasdaq Delisting Warning

Adial Pharmaceuticals received a notice from Nasdaq indicating it no longer meets the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market.

Summary

• Adial Pharmaceuticals, Inc. received a notification from Nasdaq on August 18, 2026, stating it no longer meets the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market.
• The company also does not meet the alternative quantitative standards for continued listing, such as market value of listed securities or net income.
• The notice does not immediately affect the trading of its common stock.
• Adial has 45 days (until October 2, 2026) to submit a plan to regain compliance.
• The company plans to seek stockholder approval at its 2026 Annual Meeting for the conversion of its Series A Non-Voting Convertible Preferred Stock, which it anticipates will help it regain compliance.
• There is no guarantee that this plan will be accepted by Nasdaq or that the company will regain compliance.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the company's failure to meet Nasdaq's minimum stockholders' equity requirement, raising concerns about its continued listing.

Positives

• The notice has no immediate effect on the company's continued listing or trading of its common stock on the Nasdaq Capital Market.
• The company anticipates it can regain compliance by converting its Series A Non-Voting Convertible Preferred Stock, subject to stockholder approval.

Negatives

• Adial Pharmaceuticals no longer meets the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market.
• The company also fails to meet the alternative quantitative standards for continued listing on Nasdaq.
• There is no assurance that the company's plan to regain compliance will be accepted by Nasdaq or that it will be successful.

Risks

• Failure to regain compliance with Nasdaq's stockholders' equity requirement could lead to delisting from the Nasdaq Capital Market.
• The company may not receive the necessary stockholder approval to convert its Series A Non-Voting Convertible Preferred Stock.
• Nasdaq may not accept the company's compliance plan.
• Even if the compliance plan is accepted, the company may not regain compliance within the extended period.
• If the compliance plan is not accepted or compliance is not achieved, the company may face a hearing before the Nasdaq Hearing Panel, with no guarantee of a favorable outcome.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially.

Future Outlook

The company anticipates regaining compliance by seeking stockholder approval for the conversion of its Series A Non-Voting Convertible Preferred Stock at its 2026 Annual Meeting. It intends to submit a compliance plan to Nasdaq within the required timeframe. However, there are no assurances that these actions will be successful or that Nasdaq will accept the plan.

Management Comments

• The Company currently anticipates that it will be able to take the necessary actions to regain compliance with the $2.5 million Stockholders Equity Requirement at such time that it receives stockholder approval of the conversion of its outstanding shares of Series A Non-Voting Convertible Preferred Stock, which approval it intends to seek at the Companys 2026 Annual Meeting of Stockholders; however, no assurances can be provided that it will satisfy such requirements or be able to obtain the necessary approvals at its Annual Meeting.
• The Company intends to submit a Compliance Plan, which will discuss the actions it intends to take to regain compliance with the Stockholders Equity Requirement, within the required time, monitor its stockholders equity and, if appropriate, consider further available options to regain compliance with the Stockholders Equity Requirement, although there can be no assurance that the Compliance Plan will be accepted by Nasdaq.

Industry Context

StockSavvy.ai notes that maintaining listing on major exchanges like Nasdaq is crucial for a company's visibility, liquidity, and access to capital. Failure to meet listing requirements can signal financial distress and negatively impact investor confidence.

Stakeholder Impact

• Shareholders: Potential for increased volatility and risk of delisting, which could negatively impact stock value and liquidity.
• Creditors: May view the company's financial position as weaker, potentially affecting credit terms.
• Employees: Uncertainty regarding the company's future stability could impact morale and retention.

Next Steps

• Submit a Compliance Plan to Nasdaq by October 2, 2026.
• Seek stockholder approval for the conversion of Series A Non-Voting Convertible Preferred Stock at the 2026 Annual Meeting.
• Monitor stockholders' equity and consider further options if necessary.
• If the Compliance Plan is accepted, work towards regaining compliance within the extended period (up to 180 days from August 18, 2026).
• If the Compliance Plan is not accepted or compliance is not achieved, request a hearing before the Nasdaq Hearing Panel.

Key Dates

Recommendation

The company is facing a significant risk of delisting due to failing to meet Nasdaq's financial requirements. While management has a plan involving preferred stock conversion, its success is uncertain and subject to shareholder approval and Nasdaq's acceptance. This situation warrants a cautious 'hold' stance until clarity emerges on compliance and future listing status.

Keywords

Nasdaq compliance, Stockholders Equity, Delisting Warning, Capital Market, Compliance Plan, Preferred Stock Conversion, Annual Meeting